NCT04814550 (ACCURATE) is a clinical trial of FFR in Coronary Artery Disease, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT04814550?

NCT04814550 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT04814550?

Interventions in NCT04814550: FFR.

What condition does NCT04814550 study?

NCT04814550 studies Coronary Artery Disease.

Is NCT04814550 still recruiting?

NCT04814550 is currently completed. Last updated 8 March 2023.

Last reviewed 2023-03-08 · How we verify

NCT04814550: ACCURATE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diagnostic Accuracy of CFD-Based Fractional Flow Reserve Derived From Coronary Angiography

Completed Last updated 8 March 2023

What this trial tests

trial testing FFR in Coronary Artery Disease in 318 participants. Completed in 24 February 2022.

Timeline

4 November 2020

Primary endpoint
28 June 2021

24 February 2022

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	318
Start date	4 November 2020
Primary completion	28 June 2021
Estimated completion	24 February 2022
Sites	1 location across China

Drugs / interventions tested

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

18 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, multicenter, self-control clinical trial designed to assess the efficacy of AccuFFRangio, a novel method for evaluating the functional significance of coronary stenosis from coronary angiography, with FFR as the reference standard.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Diagnostic Accuracy of Computational Fluid Dynamics-Based Fractional Flow Reserve Derived From Coronary Angiography: The ACCURATE Study.
Jiang J, Hu Y, Li C, Dong L, et al · · 2025 · cited 6× · PMID 39719423 · DOI 10.1161/jaha.124.035672

Verify or expand the search:

Other trials of FFR

Trials testing the same drug.

NCT04970082 — A Study to Evaluate Direct Wire Pacing (DWP) for Measuring Fractional Flow Reserve (FFR) · NA · completed
NCT04665817 — Diagnostic Accuracy of CCTA-derived Versus AngiogRaphy-dErived QuantitativE Flow Ratio (CAREER) Study · unknown
NCT04356027 — FUnctional diagnoSIs of corONary Stenosis (FUSION) · completed
NCT04417634 — RFR and FFR for the the Prediction of Post-PCI Results · Phase 4 · unknown
NCT04426396 — Diagnostic Performance of Fractional Flow Reserve Derived From Coronary CT Angiography · completed

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04814550 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 8 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04814550.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing